Prospective Multi-Center Observational Study to Assess Effectiveness of Venclexta (Venetoclax) in Acute Myeloid Leukemia (AML) Patients Ineligible for Standard Induction Therapy in Routine Clinical Practice in Russian Federation (INNOVATE)
Latest Information Update: 13 Mar 2023
At a glance
- Drugs Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms INNOVATE
- Sponsors AbbVie
Most Recent Events
- 08 Mar 2023 Status changed from active, no longer recruiting to completed.
- 27 Jan 2022 Planned End Date changed from 17 Aug 2023 to 20 Apr 2023.
- 27 Jan 2022 Planned primary completion date changed from 17 Aug 2023 to 20 Apr 2023.